In France, biotech firm TxCell (Euronext Paris: TXCL) and research body the National Institute for Health and Medical Research (Inserm) are entering into a biopharmaceutical research collaboration.
The research focuses on T cells, a subtype of white blood cells that are key to the body’s natural immune system.
The purpose of the collaboration is to develop therapies based on new CAR-Tregs, a unique version of the CAR-T cells currently being used by Novartis (NOVN: VX) and Kite Pharma (Nasdaq: KITE) to develop immuno-oncology therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze